1-20 of 281
Dong-Wook Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Andreas Hochhaus, Dong-Wook Kim, Jorge Cortes, Koji Sasaki, Michael Mauro, Timothy P Hughes, Massimo Breccia, Moshe Talpaz, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Fabian Lang, Michael C. Heinrich, Valle Gomez G De Soria, Philipp le Coutre, Gessami Sanchez-Olle, Jomy Jose, Nathalie Pognan, Shruti Kapoor, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 450.
https://doi.org/10.1182/blood-2023-187322
Published: 2023
Journal Articles

Novel Orally Available Degrader to Target Lck in T-Cell Acute Lymphoblastic Leukemia

Na-Rae Jeong, Ye Seul Lim, Sun-Mi Yoo, Han Wool KIM, So Hyuk Kim, Ae-Ran Choi, Dong-Wook Kim, Song Hee Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2262.
https://doi.org/10.1182/blood-2023-185778
Published: 2023
Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 866.
https://doi.org/10.1182/blood-2023-182100
Published: 2023
Journal Articles

A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia

Ye Seul Lim, Na-Rae Jeong, Sun-Mi Yoo, Han Wool KIM, Song Hee Lee, Dong-Wook Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 5012.
https://doi.org/10.1182/blood-2023-180442
Published: 2023
Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Michael Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergei Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge Cortes, Andre N.R. Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García Gutiérrez, Koji Sasaki, Carla Maria Boquimpani De Moura Freitas, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4536.
https://doi.org/10.1182/blood-2023-186854
Published: 2023
Journal Articles

Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia

Sewon Lee, Hongtae Kim, Semin Lee, Seunghoon Kim, Sung-Ho Park, Sung-Hyun Kim, Young Rok Do, Soo-Hyun Kim, Kyung-Mi Kee, Dong-Wook Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 1806.
https://doi.org/10.1182/blood-2023-178408
Published: 2023
Journal Articles

KF1601, a Novel Orally Bioavailable Inhibitor of BCR-ABL1 T315I without Inducing Thrombotic Microangiopathy

Sung-Min Ahn, Dong-Wook Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 6352.
https://doi.org/10.1182/blood-2023-190891
Published: 2023
Journal Articles

Highly Sensitive Chip-Based Digital PCR Platform for Quantitative Detection of BCR::ABL1 Transcripts throughout CML Treatment

Hyun-Woo Song, Sung-Hyun Kim, Young Rok Do, Kyung-Mi Ki, Soo Hyun Kim, Min-Sik Song, Seung-Shick Shin, Dong-Wook Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 1805.
https://doi.org/10.1182/blood-2023-185162
Published: 2023
Journal Articles

Chip-Based Digital PCR Platform, Lab on an Array, the Newly Developed Highly Accurate and Sensitive Method for the Detection of BCR-ABL1 Transcripts in Chronic Myeloid Leukemia

Hyun-Woo Song, Kyung-Mi Ki, Soo Hyun Kim, Sung-Hyun Kim, Min-Sik Song, Do Young Lee, Seung-Shick Shin, Dong-Wook Kim
Journal: Blood
Blood (2022) 140 (Supplement 1): 3904–3905.
https://doi.org/10.1182/blood-2022-168020
Published: 2022
Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Ekaterina Yu. Chelysheva, Anna Turkina, Jane F. Apperley, Mohamed A Yassin, Delphine Rea, Franck E. Nicolini, Daniela Barraco, Konstantin Kotlyarchuk, Khamida Kazakbaeva, Sukhrob Saliev, Adi Shacham, Dong-Wook Kim, Salam Al-Kindi, Penka Ganeva, Roman Shmakov, Jennifer Byrne, Harry Robertson, Cerrano Marco, Evgenia Polushkina, Malgorzata Monika Trawinska, Elisabetta Abruzzese
Journal: Blood
Blood (2022) 140 (Supplement 1): 1498–1500.
https://doi.org/10.1182/blood-2022-159993
Published: 2022
Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, Yesid Alvarado, Franck E. Nicolini, Krishnakumar Rathnam, Navin Khattry, Sachin Punatar, Jane F. Apperley, Aude Charbonnier, Michael Deininger, Hugues de Lavallade, Nikki Granacher, Carlo Gambacorti-Passerini, Alessandro Lucchesi, Michael Mauro, Peter Vandenberghe, Gregor Verhoef, Andrew R. Whiteley, Arijit Nag, Shashikant Apte, Siu-Long Yao, Sandeep Inamdar, Ruchika Irene Dillu, Jayasree Sreenivasan, Geetanjali Chimote
Journal: Blood
Blood (2022) 140 (Supplement 1): 205–207.
https://doi.org/10.1182/blood-2022-166452
Published: 2022
Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio
Journal: Blood
Blood (2022) 140 (Supplement 1): 195–197.
https://doi.org/10.1182/blood-2022-167177
Published: 2022
Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio
Journal: Blood
Blood (2022) 140 (Supplement 1): 9647–9649.
https://doi.org/10.1182/blood-2022-164444
Published: 2022
Journal Articles

Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML

CME Clinical Trials & Observations
Gi-June Min, Byung-Sik Cho, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Kim Hee-Je
Journal: Blood
Blood (2022) 139 (11): 1646–1658.
https://doi.org/10.1182/blood.2021013671
Published: 2022
Includes: Supplemental data
Journal Articles

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Clinical Trials & Observations
Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentin García-Gutiérrez, Jorge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
Journal: Blood
Blood (2021) 138 (21): 2031–2041.
https://doi.org/10.1182/blood.2020009984
Published: 2021
Includes: Supplemental data
Journal Articles

Comparison of Prognostic Impact between the European Leukemia Net (ELN) 2017 Risk Classification and Pre-Transplant WT1 expression in Patients Receiving Allogeneic Transplantation for Acute Myeloid Leukemia (AML)

Tong-Yoon Kim, Byung Sik Cho, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Hee-Je Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 3459.
https://doi.org/10.1182/blood-2021-152932
Published: 2021
Journal Articles

Early Bone Marrow Assessment after 7+3 Induction Chemotherapy Is Predictable of Outcome in AML with Adverse Cytogenetics

Daehun Kwag, Byung-Sik Cho, Gi-June Min, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 3386.
https://doi.org/10.1182/blood-2021-154385
Published: 2021
Journal Articles

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, Yesid Alvarado, Franck E. Nicolini, Krishnakumar Rathnam, Navin Khattry, Jane F Apperley, Michael W. Deininger, Hugues de Lavallade, Aude Charbonnier, Nikki Granacher, Carlo Gambacorti-Passerini, Alessandro Lucchesi, Michael J. Mauro, Peter Vandenberghe, Gregor Verhoef, Andrew R. Whiteley, Arijit Nag, Vivek S Radhakrishnan, Shashikant Apte, Siu-Long Yao, Sandeep Inamdar, Jayasree Sreenivasan, Ruchika Irene Dillu, Geetanjali Chimote
Journal: Blood
Blood (2021) 138 (Supplement 1): 309.
https://doi.org/10.1182/blood-2021-152548
Published: 2021
Journal Articles

Geriatric Assessment Predicts Non-Fatal Toxicities and Survival for Intensively Treated Elderly Acute Myeloid Leukemia: A Prospective Study

Gi June Min, Byung Sik Cho, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 222.
https://doi.org/10.1182/blood-2021-151776
Published: 2021
Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 310.
https://doi.org/10.1182/blood-2021-152561
Published: 2021